Clinical Trials

According to the EMA, around 4,000 trials are authorised each year across the EEA and this phenomenal effort, in partnership with other global research partners is transforming the way we care for patients and treat many diseases. Over the last 60 years, life expectancy across the EU has increased by nearly a decade. Since the 1980s, death rates from HIV have fallen by around 80% and since the 1990s, death rates from cancer have fallen by 20%. Hepatitis C can now, in most cases, be cured, and advances in targeted, precision medicines are transforming the way we will treat patients in the future.

You can find out more about clinical trials here.

Since the publication of the EPFIA/PhRMA principles for responsible sharing of clinical trial data, companies have made great progress in developing processes for clinical trial data access schemes, translating principles into practice. We are now seeing data being shared with researchers through some particularly innovative solutions and processes. You see data sharing case studies below.

Companies are also aligning their policies to the new EU Clinical Trials Regulation 536/2014 and the European Medicines Agency’s transparency policies: Access to Documents (Policy 0043) and Publication and access to clinical-trial data (Policy 0070).

Clinical trials are evolving with new approaches, technologies and designs. They remain an essential part of medical research as they aim at providing the community with the latest innovative treatments and state-of-the-art clinical practice.